|
Date
|
Update
|
|
15 June 2020
|
The Department for Health and Social Care has asked NICE to conduct an appraisal of Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer.
Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.
|
|
08 August 2019
|
As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer.
Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. |
|
04 January 2019
|
As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab plus chemotherapy as a neo-adjuvant therapy in patients with previously untreated locally advanced non-metastatic triple negative breast cancer. I am writing to advise that following an update from the company, NICE has rescheduled the appraisal and it is expected to begin in mid-July 2019. |
|
15 October 2018 - 12 November 2018
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
|
26 June 2018
|
In progress. Topic referred |